Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Essai de phase 1/2 sur la radiothérapie en association avec le TTI-101 chez des patients atteints d'un cancer du pancréas limite résécable

3 novembre 2026 mis à jour par: Washington University School of Medicine

The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial invigoration of immune response, and relief of symptom burden, SBRT has not demonstrated any improvement in survival. Preclinical research has established that STAT3 inhibition given concurrently with SBRT and in the maintenance phase acts as a synergistic agent that enhances the pro-inflammatory effects of SBRT while reducing its undesired effects (including fibrosis and immunosuppression). This study exploits the window of opportunity post-chemotherapy to advance the hypothesis that the addition of STAT3 inhibition in combination with SBRT will be safe and will enhance 2-year progression-free survival.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

24

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Complété
        • University of Colorado
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University School of Medicine
        • Sous-enquêteur:
          • Olivia Aranha, M.D., Ph.D.
        • Sous-enquêteur:
          • Kian-Huat Lim, M.D.
        • Sous-enquêteur:
          • Patrick Grierson, M.D., Ph.D.
        • Sous-enquêteur:
          • Dominic Sanford, M.D.
        • Sous-enquêteur:
          • Rama Suresh, M.D.
        • Sous-enquêteur:
          • Caron Rigden, M.D.
        • Sous-enquêteur:
          • Moh'd Khushman, M.D.
        • Sous-enquêteur:
          • Roheena Panni, M.D.
        • Sous-enquêteur:
          • Nikolaos Andreatos, M.D.
        • Sous-enquêteur:
          • Ramon Jin, M.D., Ph.D.
        • Sous-enquêteur:
          • Michael Waters, M.D., Ph.D.
        • Sous-enquêteur:
          • Chunjie Li, M.D., Ph.D.
        • Contact:
        • Chercheur principal:
          • Sana Karam, M.D., Ph.D.
        • Sous-enquêteur:
          • Joseph Harms, Ph.D., DABR
        • Sous-enquêteur:
          • Trang Nguyen, M.D.
        • Sous-enquêteur:
          • Ben Tan, M.D.
        • Sous-enquêteur:
          • Junxiao Hu, Ph.D.

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Pathologically confirmed pancreatic adenocarcinoma that is borderline resectable or locally advanced as defined by NCCN guidelines, with no expected arterial resection/reconstruction.

  • Patients who are borderline resectable must have completed standard of care induction chemotherapy between 1 and 3 weeks prior to planned start of TTI-101 + SBRT. Patients who exceed this window may be considered for enrollment if they complete an additional cycle of induction chemotherapy prior to initiation of study treatment (per provider discretion). The receipt and/or amount of induction chemotherapy cycles allowed will be left to the discretion of the treating medical oncologist. There is no timing restriction or chemotherapy receipt for patients with locally advanced disease.

  • At least 18 years of age.

  • ECOG performance status ≤ 2

  • Adequate bone marrow and organ function as defined below:

    • Absolute neutrophil count ≥ 1.0 K/cumm
    • Platelets ≥ 70 K/cumm
    • Hemoglobin ≥ 9.0 g/dL (patients may be transfused to meet this criterion)
    • Total bilirubin ≤ 2 mg/dL
    • AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
    • Serum albumin ≥ 2.8 g/dL
    • Ionized calcium ≤ 1.5 mmol/L, calcium ≤ 12 mg/dL, or corrected serum calcium ≤ IULN)
    • Measured creatinine clearance > 40 mL/min or calculated creatinine clearance > 40 mL/min by Cockcroft-Gault or by 24-hour urine collection for determination of creatinine clearance (calculations in protocol).
  • Able to swallow pills and has been deemed an appropriate candidate for investigational TTI-101 treatment based on the opinion of both the treating radiation oncologist and the treating medical oncologist.

  • INR and aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy (in which case INR and PTT must be within therapeutic range of intended use of anticoagulants)

  • The effects of TTI-101 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use at least 1 highly effective method of contraception from screening through the duration of study participation, and for 30 days after last dose of TTI-101. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform the treating physician immediately.

  • Agreement to adhere to Lifestyle Considerations throughout study duration.

  • Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria:

  • Prior irradiation of pancreatic cancer in the past 2 years.
  • Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
  • Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device overlapping with study treatments within 3 months preceding study entry at the discretion of the PI.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to TTI-101 or other agents used in the study.
  • Uncontrolled intercurrent illness including but not limited to: ongoing or active infection (fungal, bacterial, or viral (including COVID-19)), sepsis, acute and chronic active infectious disorders (including viral and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy), and chronic pancreatitis. Patients with a recent COVID-19 diagnosis must have fully recovered from all COVID-19 symptoms for 2 weeks prior to the start of study treatment.
  • Significantly impaired cardiac function such as symptomatic congestive heart failure with NYHA Class III or IV, unstable angina pectoris, myocardial infarction within the last 12 months prior to study entry, serious cardiac arrhythmia (including QTc prolongation of > 470 ms and/or pacemaker), or prior diagnosis of congenital long QT syndrome.
  • Ongoing toxicity due to induction chemotherapy, unless returned to baseline or grade 1 or less (except alopecia and labs noted in inclusion criterion #5).
  • Has had major surgery within 3 weeks prior to starting TTI-101 or has not recovered from major side effects due to surgery.
  • Presence of pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequent). Participants with indwelling catheters for control of effusions or ascites are allowed.
  • History of cerebrovascular accident or stroke within the previous 2 years.
  • History of hepatic encephalopathy.
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
  • History of malabsorption or other chronic gastrointestinal disease or condition that may hamper compliance or absorption of TTI-101.
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 5 days of study entry.
  • HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.
  • Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.
  • History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: TTI-101 + SBRT Dose Level 0 (original starting dose)
  • Treatment consists of TTI-101 by mouth twice daily at 400 mg and SBRT (5 fractions of 6.6 Gy each) over the course of 3 weeks.
  • After combination therapy is concluded, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9 and 13). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation).
  • Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

Given at the assigned dose assigned in the protocol.

Given at the assigned dose and fractions assigned in the protocol.

Autres noms:
  • SBRT
Expérimental: TTI-101 + SBRT Dose Level -1 (WUSM starting dose)
  • Treatment of TTI-101 by mouth twice daily at 200 mg & SBRT (3 fractions of 6 Gy each, approximately every other day but may be given over 2-3 weeks) over the course of 3 weeks.
  • After combination therapy, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9-13 if possible). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation).
  • Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

Given at the assigned dose assigned in the protocol.

Given at the assigned dose and fractions assigned in the protocol.

Autres noms:
  • SBRT
Expérimental: TTI-101 + SBRT Dose Level -2
  • Treatment consists of TTI-101 by mouth twice daily at 200 mg and SBRT (1 fraction of 12 Gy each) over the course of 3 weeks.
  • After combination therapy is concluded, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9 and 13 if possible). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation).
  • Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

Given at the assigned dose assigned in the protocol.

Given at the assigned dose and fractions assigned in the protocol.

Autres noms:
  • SBRT
Expérimental: TTI-101 + SBRT Expansion Phase
  • Treatment consists of TTI-101 by mouth twice daily at the RP2D dose and SBRT (at the RP2D dose and timing) over the course of 3 weeks.
  • After combination therapy is concluded, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9 and 13 if possible). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation).
  • Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

Given at the assigned dose assigned in the protocol.

Given at the assigned dose and fractions assigned in the protocol.

Autres noms:
  • SBRT

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of TTI-101 and SBRT
Délai: Through completion of follow-up (estimated to be 2 years and 3 months)
  • The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the dose-limiting toxicity (DLT) evaluation period.
  • The final determination of the RP2D will be based on an overall evaluation of the totality of the available data observed in phase IB.
Through completion of follow-up (estimated to be 2 years and 3 months)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS)
Délai: 2 years

PFS is defined as the time from treatment initiation to documented disease progression or death from any cause. The 2-year PFS probability will be reported as a descriptive summary measure.

2 years
Overall survival (OS)
Délai: 2 years

OS is defined as the time from treatment initiation to death from any cause. The 2-year OS probability will be reported as a descriptive summary measure.

2 years
Pathologic response rate
Délai: At the time of surgery (estimated to be 5 weeks)
  • Pathologic response rate among patients who receive neoadjuvant TTI-101 in combination with SBRT and subsequently undergo surgical resection (including pCR and/or major pathologic response).
  • Pathologic complete response (pCR) is defined as the absence of any vital tumor tissue in the sampled pancreatic resection specimen.
  • Major pathologic response is defined as ≤ 10% residual viable tumor cells remaining in the surgical specimen after treatment.
At the time of surgery (estimated to be 5 weeks)
R0 resection rate among patients who undergo surgical resection
Délai: At the time of surgery (estimated to be 5 weeks)

R0 resection is defined as microscopic tumor clearance in the pancreatic resection specimen.

At the time of surgery (estimated to be 5 weeks)
Frequency of adverse events
Délai: From start of treatment through 90 days after last dose of TTI-101 (estimated to be 6 months)

Graded according to NCI CTCAE v 5.0.

From start of treatment through 90 days after last dose of TTI-101 (estimated to be 6 months)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Sana Karam, M.D., Ph.D., Washington University School of Medicine

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 janvier 2024

Achèvement primaire (Estimé)

30 juin 2029

Achèvement de l'étude (Estimé)

30 juin 2029

Dates d'inscription aux études

Première soumission

8 novembre 2023

Première soumission répondant aux critères de contrôle qualité

14 novembre 2023

Première publication (Réel)

21 novembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner